AI-generated analysis. Always verify with the original filing.
Quoin Pharmaceuticals Ltd. announced Q4 and full-year 2025 financial results with net loss of $4.3 million and $15.8 million respectively, cash position of $18.7 million funding into 2027, closed $104.5 million private placement financing, and key regulatory progress for QRX003 including Orphan Drug and Fast Track Designations for Netherton Syndrome.
Event Type
Disclosure
Mandatory
Variant
8-K
shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated March 26, 2026 104 Cover Page Interactive Data file (embedded
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $4.30 | |
| Net Loss | $15.80 |